Anton F. H. Stalenhoef

Anton F. H. Stalenhoef's AcademicInfluence.com Rankings

Philosophy

#7858

World Rank

#11128

Historical Rank

Logic

#4892

World Rank

#6227

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Anton F. H. Stalenhoef's Degrees

PhD Biomedical Sciences University of Amsterdam
Masters Biomedical Sciences University of Amsterdam
Bachelors Biomedical Sciences University of Amsterdam

Why Is Anton F. H. Stalenhoef Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Anton F. H. Stalenhoef's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) (1786)
Simvastatin with or without ezetimibe in familial hypercholesterolemia. (2008) (954)
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit (2007) (911)
Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. (1991) (745)
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. (2012) (662)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) (545)
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. (2007) (540)
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel (2006) (478)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) (470)
Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study (2002) (468)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. (2014) (442)
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance (2006) (382)
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. (2015) (381)
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200189-JLR200 (2002) (354)
Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. (1992) (342)
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. (2001) (337)
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans (2007) (312)
LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. (1996) (277)
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. (2010) (266)
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. (2010) (258)
A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200 (2004) (256)
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis (2004) (224)
Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2. (2011) (212)
Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. (1996) (203)
Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. (1999) (201)
Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome (2004) (199)
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin (2011) (181)
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. (2015) (180)
Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. (1998) (175)
Compromised LCAT Function Is Associated With Increased Atherosclerosis (2005) (167)
Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. (1984) (164)
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis (2007) (163)
Red wine consumption does not affect oxidizability of low-density lipoproteins in volunteers. (1996) (161)
Hyperglycemia Activates Caspase-1 and TXNIP-Mediated IL-1β Transcription in Human Adipose Tissue (2011) (158)
Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects (1998) (148)
Serum triglycerides and risk of cardiovascular disease. (2012) (143)
Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. (1993) (139)
Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study (2002) (137)
Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. (1997) (136)
The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. (2000) (135)
Non‐LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll‐like receptor 2‐dependent pathways (2002) (134)
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. (2003) (132)
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. (2002) (131)
Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study (2004) (131)
Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. (2006) (127)
The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. (2000) (118)
Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL (2008) (118)
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. (2005) (116)
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients (2008) (115)
Effects of Peritoneal Dialysis with an Overnight Icodextrin Dwell on Parameters of Glucose and LIPID Metabolism (2001) (114)
Cholesterol-raising factor from boiled coffee does not pass a paper filter. (1991) (111)
Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects. (1993) (109)
Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells (2000) (108)
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. (1995) (108)
Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe (2010) (107)
Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. (1987) (105)
alpha-tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals. (2000) (104)
Effect of Apheresis of Low-Density Lipoprotein on Peripheral Vascular Disease in Hypercholesterolemic Patients with Coronary Artery Disease (1996) (102)
Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. (1991) (99)
The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue. (2011) (99)
Decreased in vitro oxidizability of low‐density lipoprotein in hypercholesterolaemic patients treated with 3‐hydroxy‐3‐methyIgIutaryl‐CoA reductase inhibitors (1993) (97)
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400052-JLR200 (2005) (95)
The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk (2003) (95)
Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. (1994) (95)
What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction? (2007) (94)
Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels. (2002) (92)
The genetics of familial combined hyperlipidaemia (2012) (91)
The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. (2006) (90)
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. (2004) (90)
Serum carotenoids, alpha-tocopherol and mortality risk in a prospective study among Dutch elderly. (2001) (89)
Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development (2013) (86)
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. (1990) (85)
Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. (2000) (85)
Answers to Questions Posed During Daily Patient Care Are More Likely to Be Answered by UpToDate Than PubMed (2008) (85)
The role of TNF- a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk (2007) (85)
Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. (1999) (84)
The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. (1995) (83)
Increased oxidizability of low-density lipoproteins in hypothyroidism. (1998) (83)
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. (2001) (83)
Combined deficiency of apolipoprotein C-II and lipoprotein lipase in familial hyperchylomicronemia. (1981) (83)
Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). (1996) (82)
Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families. (1992) (79)
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia. (1988) (79)
Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. (2003) (79)
Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. (2001) (78)
Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis (2009) (78)
Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance. (1990) (78)
Effects of ubiquinone (coenzyme Q10) on myopathy in statin users (2008) (77)
Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. (1997) (76)
Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial (2005) (74)
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. (2010) (74)
Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. (1996) (74)
The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. (1996) (73)
C-Reactive Protein and Annexin A5 Bind to Distinct Sites of Negatively Charged Phospholipids Present in Oxidized Low-Density Lipoprotein (2005) (71)
Two novel molecular defects in the LCAT gene are associated with fish eye disease. (1996) (71)
Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. (1986) (71)
Defects of lipoprotein metabolism in familial combined hyperlipidaemia. (1998) (70)
The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. (2009) (69)
Increased Levels of Low-Density Lipoprotein Oxidation in Patients with Familial Hypercholesterolemia and in End-Stage Renal Disease Patients on Hemodialysis (2003) (68)
Variation in non-invasive measurements of vascular function in healthy volunteers during daytime. (2005) (68)
A deletion mutation in the ApoC-II gene (ApoC-II Nijmegen) of a patient with a deficiency of apolipoprotein C-II. (1988) (66)
Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3. (1983) (61)
Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4. (1989) (61)
Cardiac complication after experimental human malaria infection: a case report (2009) (60)
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. (2005) (59)
Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. (1995) (58)
Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. (2008) (57)
Influence of contraceptive pill and menstrual cycle on serum lipids and high-density lipoprotein cholesterol concentrations. (1982) (57)
The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia (2006) (55)
Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release. (2004) (55)
Role of Insulin Resistance in Familial Combined Hyperlipidemia (2005) (54)
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. (1998) (54)
Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. (1998) (52)
Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. (2006) (51)
Analysis of queries sent to PubMed at the point of care: Observation of search behaviour in a medical teaching hospital (2008) (51)
Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia. (1997) (51)
Expression of Type III Hyperlipoproteinemia in Apolipoprotein E2 (Arg158→Cys) Homozygotes Is Associated With Hyperinsulinemia (2002) (50)
HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA IN THE NETHERLANDS: PREVALENCE, GENOTYPE-PHENOTYPE RELATIONSHIP AND CLINICAL OUTCOME (2014) (50)
Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? (2009) (49)
The expression of type III hyperlipoproteinemia: involvement of lipolysis genes (2009) (45)
Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. (2002) (45)
The prevalence of peripheral vascular disease in familial hypercholesterolaemia (1995) (44)
[The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board]. (2006) (43)
The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemias⃞ Published, JLR Papers in Press, October 25, 2006. (2007) (42)
Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. (2009) (41)
Effects of Atorvastatin and Simvastatin on Low-Density Lipoprotein Subtraction Profile, Low-Density Lipoprotein Oxidizability, and Antibodies to Oxidized Low-Density Lipoprotein in Relation to Carotid Intima Media Thickness in Familial Hypercholesterolemia (2004) (41)
Oxidative Stress in Patients with End-Stage Renal Disease prior to the Start of Renal Replacement Therapy (2004) (41)
A study of the lipid transport system in the cat, Felix domesticus. (1987) (41)
Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls. (1993) (40)
Towards a role of interleukin-32 in atherosclerosis. (2013) (40)
Efficacy and tolerability of simvastatin (MK-733). (1989) (40)
Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. (2001) (40)
Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. (2014) (39)
Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. (1994) (39)
Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. (2010) (38)
The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. (1993) (38)
Decreased resistance against in vitro oxidation of LDL from patients with familial defective apolipoprotein B-100. (1994) (37)
Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study; (2004) (36)
Fine mapping of a gene responsible for regulating dietary cholesterol absorption; founder effects underlie cases of phytosterolaemia in multiple communities (2001) (36)
Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile Published, JLR Papers in Press, August 16, 2005. DOI 10.1194/jlr.M500212-JLR200 (2005) (36)
Single-spin density-gradient ultracentrifugation vs gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. (1991) (36)
Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. (1998) (35)
The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects. (2001) (35)
The benefit of statins in non-cardiac vascular surgery patients. (2009) (35)
High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study (2012) (35)
Evaluation of PubMed filters used for evidence-based searching: validation using relative recall. (2009) (34)
Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. (1991) (34)
Hypo‐ and Hyperresponse of Serum Cholesterol Level and Low Density Lipoprotein Production and Degradation to Dietary Cholesterol in Man a (1993) (33)
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia. (1985) (33)
The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. (1997) (33)
Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects (2005) (33)
Non-invasive measurements of atherosclerosis (NIMA): current evidence and future perspectives. (2010) (33)
EFFECTS OF INHIBITION OF CHOLESTEROL SYNTHESIS BY SIMVASTATIN ON THE PRODUCTION OF ADRENOCORTICAL STEROID HORMONES AND ACTH (1989) (32)
LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. (1998) (32)
Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia (2000) (32)
Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia. (2007) (32)
Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. (2004) (32)
Lipoprotein(a) Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Production by Human Mononuclear Cells (1998) (32)
The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia (1990) (31)
Pulse wave velocity in familial combined hyperlipidemia. (2007) (29)
Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice (1997) (29)
ACE inhibitors and LDL-apheresis with dextran sulphate adsorption (1992) (29)
Plasma Lipoproteins, Apolipoproteins, and Triglyceride Metabolism in Familial Hypertriglyceridemia (1986) (29)
Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. (1996) (29)
Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. (2004) (29)
Identification of apolipoprotein E polymorphism by using synthetic oligonucleotides. (1988) (28)
Plasma annexin A5 level relates inversely to the severity of coronary stenosis. (2007) (28)
Treatment of primary hypercholesterolaemia. Short‐term efficacy and safety of increasing doses of simvastatin and pravastatin: a double‐blind comparative study (1993) (28)
Differences in metabolism of three low density lipoprotein subfractions in Hep G2 cells. (1990) (27)
In vivo oxidised cholesterol in atherosclerosis. (1993) (27)
A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. (1998) (25)
Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS). (2007) (24)
Remnant particles are the major determinant of an increased intima media thickness in patients with familial combined hyperlipidemia (FCH). (2007) (24)
HYPERLIPOPROTEINAEMIA TYPE V AND APOLIPOPROTEIN E4 (1982) (24)
Plasma activities of lecithin:cholesterol acyltransferase, lipid transfer proteins and post-heparin lipases in inbred strains of rabbits hypo- or hyper-responsive to dietary cholesterol. (1993) (24)
Oxidized low-density lipoprotein induces calcium influx in polymorphonuclear leukocytes. (2000) (23)
Non-transferrin-bound iron is associated with plasma level of soluble intercellular adhesion molecule-1 but not with in vivo low-density lipoprotein oxidation. (2007) (23)
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. (1996) (23)
Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. (2013) (23)
The LDL-apheresis atherosclerosis regression study (Laars) (1992) (23)
Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria Published, JLR Papers in Press, February 1, 2004. DOI 10.1194/jlr.M300453-JLR200 (2004) (23)
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study (2003) (22)
Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia. (2007) (22)
Circulating Lipoproteins Are a Crucial Component of Host Defense against Invasive Salmonella typhimurium Infection (2009) (22)
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus (2010) (22)
Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits. (1991) (21)
The Importance of Written Information Packages in Support of Case-Finding Within Families at Risk for Inherited High Cholesterol (2006) (21)
Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients: A Pooled Analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE Studies (2010) (21)
High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. (2007) (21)
LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment. (2006) (21)
Vascular graft infection in aortoiliac and aortofemoral bypass surgery: clinical presentation, diagnostic strategies and results of surgical treatment. (2004) (21)
On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis? (1996) (20)
Increased interleukin-1alpha and interleukin-1beta production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. (1998) (20)
Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study. (2009) (20)
Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers. (1994) (20)
Phytosterol consumption and the anabolic steroid boldenone in humans: A hypothesis piloted (2007) (19)
Plasma homocysteine in subjects with familial combined hyperlipidemia. (2003) (19)
Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo. (1988) (19)
Pancreatitis induced by oestrogen in a patient with type I hyperlipoproteinaemia. (1986) (19)
Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment (2015) (19)
Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH) (2005) (19)
Cholesterol in end-stage renal disease: the good, the bad or the ugly? (2008) (19)
A study of the chylomicron metabolism in WHHL rabbits after fat loading. Discrepancy between results based on measurement of apoprotein B-48 or retinyl palmitate. (1992) (19)
Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD. (2005) (19)
A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity. (1992) (19)
The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia. (2000) (18)
The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis. (2007) (18)
A boy with autosomal recessive hypercholesterolaemia. (2004) (18)
Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. (2007) (17)
Native LDL potentiate TNF alpha and IL-8 production by human mononuclear cells. (2002) (17)
Paraoxonase Genotype, LDL-oxidation and Carotid Atherosclerosis in Male Life-long Smokers (2004) (17)
Adiponectin multimer distribution in patients with familial combined hyperlipidemia. (2008) (17)
Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia. (2005) (17)
Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia (2001) (16)
The effect of statin therapy on plasma high‐density lipoprotein cholesterol levels is modified by paraoxonase‐1 in patients with familial hypercholesterolaemia (2005) (16)
Paraoxonase (PON1) is associated with familial combined hyperlipidemia. (2008) (16)
Familial combined hyperlipidemia: from molecular insights to tailored therapy (2014) (16)
The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability. (1999) (15)
Partial ileal bypass reduces the production rate of low density lipoproteins in Watanabe heritable hyperlipidemic rabbits. (1984) (15)
JTT-705: is there still future for a CETP inhibitor after torcetrapib? (2008) (15)
Toll‐like receptor‐4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia (2004) (15)
Molecular genetics of apoC-II and lipoprotein lipase deficiency. (1991) (15)
Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia). (1990) (15)
Combining risk markers improves cardiovascular risk prediction in women. (2014) (15)
The 4S Study (1994) (14)
The role of modification of lipoproteins and of the immune system in early atherogenesis. (1993) (14)
Endothelial function in familial combined hyperlipidaemia (2007) (14)
Differences in LDL receptor-mediated metabolism of three low density lipoprotein subfractions by human monocyte-derived macrophages: impact on the risk for atherosclerosis. (1993) (14)
HIGH-DENSITY-LIPOPROTEIN AND MATURITY-ONSET DIABETES (1978) (14)
C-Reactive Protein and Annexin A 5 Bind to Distinct Sites of Negatively Charged Phospholipids Present in Oxidized Low-Density Lipoprotein (2005) (13)
Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case–control study (2011) (13)
The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. (1993) (13)
LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results* (2008) (13)
Familial combined hyperlipidemia: from molecular insights to tailored therapy. (2014) (13)
Apolipoprotein C in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia (1982) (13)
Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosis. (2006) (12)
Effect of troglitazone on lipoprotein(a) levels in obese subjects. (1999) (12)
Adrenocortical function in patients on simvastatin (1990) (12)
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. (2003) (12)
Effects of pioglitazone in familial combined hyperlipidaemia (2006) (12)
Indications for the presence of circulating peroxidized low density lipoproteins in WHHL rabbits treated with antioxidants. (1993) (11)
Running on age in a 15-km road run: minor influence of age on performance (2010) (11)
Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCII gene and the first APOCIV gene mutation: APOCII-CIV(Nijmegen). (2000) (11)
Increased hepatic lipase activity and increased direct removal of very-low-density lipoprotein remnants in Watanabe heritable hyperlipidaemic (WHHL) rabbits treated with ethinyl oestradiol. (1990) (11)
The case for case reports in the Netherlands Journal of Medicine. (2006) (10)
Chylomicron processing in familial dysbetalipoproteinemia and familial combined hyperlipidemia studied with vitamin A and E as markers: a new physiological concept. (2000) (10)
Chondrosarcoma coexistent with dermatomyositis. (1986) (10)
Changing aspects of HFE-related hereditary haemochromatosis and endeavours to early diagnosis. (2007) (10)
Beta-VLDL accumulation in familial dysbetalipoproteinemia is associated with increased exchange or diffusion of chylomicron lipids to apo B-100 containing triglyceride-rich lipoproteins. (1998) (10)
Annexin A5 haplotypes in familial hypercholesterolemia: lack of association with carotid intima-media thickness and cardiovascular disease risk. (2015) (9)
Familial apolipoprotein CII deficiency: A preliminary analysis of the gene defect in two independent families (1984) (9)
A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial (2001) (9)
Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study (2009) (9)
The lipoprotein lipase (ASN291→SER) mutation is associated with elevated lipid levels in familial combined hyperlipidemia (1995) (8)
Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity. (2005) (8)
HMG-CoA-reductase-inhibitors (1993) (8)
The effect of the initiation of renal replacement therapy on lipid profile and oxidative stress during the first 6 months of treatment. (2005) (8)
W16-P-087 Effects of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidemia (FCH) (2005) (8)
Anti-TNF therapy and plasma HDL cholesterol concentration. (2005) (8)
The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. (1990) (7)
Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias (2011) (7)
Oxidation of low-density lipoproteins by acellular components of Chlamydia pneumoniae. (2000) (7)
Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS) (1996) (6)
Efficacy, Safety and Tolerability of Simvastatin in Children with Familial Hypercholesterolaemia (2002) (6)
Fingerprick cholesterol testing with the "Reflotron". (1988) (6)
Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis. (1990) (6)
[Use of margarine fortified with phytosterols as a therapeutic food]. (2000) (5)
HMG-coenzym a reductase inhibitors: drugselection by means of the soja method (1999) (5)
Phytosterolemia and Xanthomatosis (2003) (5)
Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia. (1995) (5)
Native LDL potentiate TNFα and IL-8 production by human mononuclear cells DOI 10.1194/jlr.M100254-JLR200 (2002) (4)
Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension. (1999) (4)
SCANDINAVIAN SIMVASTATIN STUDY (4S). AUTHORS' REPLY (1994) (4)
Apolipoprotein CII (apo CII) gene expression defect in an individual with familial apo CII deficiency. (1987) (4)
Annexin A 5 haplotypes in familial hypercholesterolemia : Lack of association with carotid intima-media thickness and cardiovascular disease risk (2014) (4)
Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin. (1997) (4)
Low-density lipoprotein catabolism in WHHL rabbits after partial ileal bypass surgery. (1989) (4)
Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate. (1982) (4)
Changes in the editorial staff of the Journal (2005) (4)
Neutrophil superoxide-anion generating capacity in chronic smoking: Effect of long-term α-tocopherol therapy (2003) (4)
CHOLESTEROL SYNTHESIS INHIBITORS IN HYPERLIPIDAEMIA (1988) (4)
Can we exclude the TXNIP gene as a candidate gene for familial combined hyperlipidemia? (2006) (4)
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia. (1998) (3)
The V 73 M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia (2000) (3)
Fat loading experiments with the vitamins A and E suggest that in postprandial lipemia transfer/diffusion of chylomicron lipids to VLDL contributes to beta-VLDL formation. (1998) (3)
Plasma levels of lipid and cholesterol oxidation products and in diabetes mellitus and cigarette smoking : of vitamin treatment (2017) (3)
Metabolism: Editorial Comment (1990) (3)
Should preclinical vascular abnormalities be measured in asymptomatic adults to improve cardiovascular risk stratification? (2011) (3)
The 19th annual meeting of the European Lipoprotein Club. (1997) (3)
Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained? (2008) (3)
[Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant]. (2000) (3)
Clinical implications of increased low-density lipoprotein oxidation in patients with hypercholesterolemia. (1994) (3)
Fatty acids engagement with TLR2 drive IL-1 β production via ASC-caspase-1 pathway by urate crystals in gouty arthritis (2011) (2)
W05-P-006 The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase type 1 (2005) (2)
Scandinavian simvastatin study (4S) (1994) (2)
ADIPONECTIN MULTIMER DISTRIBUTION IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA (2008) (2)
Apo E polymorphism and the removal of remnants of triglyceride-rich lipoproteins in normolipidemic subjects during a carbohydrate-rich diet. (1989) (2)
Management of mixed hyperlipidaemia. (2005) (2)
Severe hypertriglyceridaemia associated with altered apolipoprotein C and E composition of the triglyceride-rich lipoproteins. (1981) (2)
The 17th annual meeting of the European Lipoprotein Club. (1996) (2)
Dominant type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia). (2013) (2)
The Netherlands Journal of Medicine's hit list: best cited articles in 2003. (2005) (2)
[Hereditary haemochromatosis: novel genes, novel diseases and hepcidin]. (2007) (2)
Interaction Between Genes and Environment in Inherited Lipid Disorders Determines Clinical Presentation (2002) (2)
Images in clinical medicine. Phytosterolemia and xanthomatosis. (2003) (2)
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure]. (2006) (2)
[Serum triglycerides as a risk factor for atherosclerosis]. (1999) (2)
Low-density lipoprotein turnover in inbred strains of rabbits hypo- or hyperresponsive to dietary cholesterol (1992) (2)
Reducing cardiac after-load by lowering blood viscosity in patients with familial hypercholesterolemia – A pilot study. Possible mechanism for occurrence of anemia in chronic heart failure patients? (2016) (2)
Transient bilateral cortical blindness as a presenting symptom of infective endocarditis. (1996) (2)
Dalcetrapib in High-Risk Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome (2009) (2)
[Efficacy and safety of simvastatin, a new cholesterol-lowering drug]. (1989) (2)
Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008. (2008) (2)
The LDL-Apheresis Atherosclerosis Regression Study (LAARS)(Symposium 7: LDL and Lp(a) Apheresis) (1997) (2)
The 16th annual meeting of the European Lipoprotein Club. (1994) (2)
[Statins available from chemist shops will not positively affect health]. (2007) (2)
An additional MspI RFLP at the human hepatic lipase (HL) gene locus. (1990) (1)
Why publish in the Netherlands Journal of Medicine (2003) (1)
[Broader indication for treatment with statins; the 'heart protection study']. (2002) (1)
Indications for a contribution of paraoxonase type-1 to plasma high density lipoprotein levels in patients with familial hypercholesterolemia (2004) (1)
Low Density Lipoprotein Apheresis Improves Regional Myocardial Perfusion in Patients With Hypercholesterolemia and Extensive Coronary Artery Disease (2019) (1)
The hemochromatosis family study (HEFAS): Increased morbidity and similar mortality compared to controls (2006) (1)
Lipoprotein levels and oxidizability of LDL during long-term LDL-apheresis (1994) (1)
Primary dyslipidemia in Dutch general practice (1994) (1)
Increased Removal of / 8-Very Low Density Lipoproteins After Ethinyl Estradiol Is Associated With Increased mRNA Levels for Hepatic Lipase , Lipoprotein Lipase , and the Low Density Lipoprotein Receptor in Watanabe Heritable Hyperlipidemic Rabbits (2005) (1)
The dense low-density lipoprotein (LDL) subfractions are more potent than buoyant LDL for binding and neutralization of lipopolysaccharide (1997) (1)
Alterations in the metabolism of very-low- and low-density lipoproteins after partial ileal-bypass surgery in the Watanabe heritable hyperlipidaemic rabbit. (1991) (1)
[Clinical significance of current perspectives in cholesterol metabolism]. (1986) (1)
W12-P-071 Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with the metabolic syndrome: Results from the comets study (2005) (1)
ANTI-INFLAMMATORY THERAPY WITH TNF-ALPHA INHIBITORS IMPROVES HDL-CHOLESTEROL ANTI-ATHEROGENIC CAPACITY IN RHEUMATOID ARTHRITIS PATIENTS (2008) (1)
Antioxidative intervention alone does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits (1994) (1)
Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial". (2005) (1)
Th e CETP inhibitor Torcetrapib and Off -target Toxicity A Pooled Analysis of the RADIANCE Trials. (2008) (1)
First-degree relatives of C282Y homozygous probands with clinically detected hemochromatosis have increased morbidity compared to the general population. The hemochromatosis family study (HEFAS) (2007) (1)
Impact factor of the Netherlands Journal of Medicine. (2007) (1)
818 GENDER SPECIFIC IMPACT OF INFLAMMATION AND OBESITY ON SUBCLINICAL ATHEROSCLEROSIS IN THE GENERAL POPULATION (2011) (1)
The Molecular Basis of ApoC-II Deficiency (1989) (0)
Th-P15:240 The effect of ageing and obesity on the expression of dyslipidemia in children from FCH families (2006) (0)
Casus 39 – Antwoord (2012) (0)
The higher interleukin-1 production by LPS-stimulated macrophages of LDL-receptor knock-out mice is a CD11c/CD18-mediated phenomenon (1997) (0)
Casus 24 – Antwoord (2012) (0)
Casus 10 – Antwoord (2012) (0)
Familial combined hyperlipidemia (1996) (0)
Safety and Tolerability of Dalcetrapib in High-Risk Patients with Type 2 Diabetes and/or Metabolic Syndrome (2009) (0)
Familial hypercholesterolemia in childhood : diagnostics , therapeutical options and risk stratification (2009) (0)
[Triglycerides and atherosclerosis; treatment of hypertriglyceridemia]. (1994) (0)
Abstract: 47 EVIDENCE OF INCREASED CHOLESTEROL SYNTHESIS IN FAMILIAL COMBINED HYPERLIPIDEMIA (2009) (0)
Casus 31 – Antwoord (2012) (0)
P303 THE DIAGNOSTIC ALGORITHM FOR apoB DYSLIPOPROTEINEMIAS APPLIED TO THE DUTCH POPULATION (2010) (0)
[The added value of a structured evaluation of patients with vascular disease]. (2002) (0)
Casus 27 – Antwoord (2012) (0)
Blurred vision. (2007) (0)
A patient with Fish Eye Disease (FED): increased risk for CHD? (1994) (0)
Chapter 4 Primary dyslipidaemias (2011) (0)
[How to prevent reoperation of an already existing bypass on a coronary bypass]. (1987) (0)
Casus 14 – Antwoord (2012) (0)
[The number of carotid operations in the Medical Spectrum Twente before and after the publication of pertinent international research on the need for endarterectomy for A. carotis stenosis]. (1998) (0)
['Cholesterol' guidelines (first revision) of the Dutch College of Family Physicians; response from internal medicine]. (2000) (0)
LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update. (1997) (0)
Association between PWV and different definitions of the metabolic syndrome (2008) (0)
Coronary artery disease in the LDL-Apheresis atherosclerosis regression study (LAARS) (1995) (0)
Hemochromatosis family study (HEFAS) : Homozygous C282Y-HFE-mutated siblings have highest risk for clinical features (2006) (0)
Ultracentrifugationin Swinging-Bucketand Fixed-AngleRotors Evaluatedfor Isolationand Determinationof High-DensityLipoproteinSubfractionsHDL2 and HDL3 (1983) (0)
Casus 7 – Antwoord (2012) (0)
Casus 37 – Antwoord (2012) (0)
Casus 23 – Antwoord (2012) (0)
Non-obese patients with familial combined hyperlipidemia are insulin resistant compared with normolipidemic controls (1995) (0)
Abstracts of papers clinical pharmacological meeting (2005) (0)
Casus 30 – Antwoord (2012) (0)
PCV9 DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR CARDIOVASCULAR EVENTS AMONG 92035 USERS OF STATINS IN A REAL LIFE SETTING (2007) (0)
Journal of Medicine Elsevier Effects of Gemfibrozil or Simvastatin on Apolipoprotein-b-containing Lipoproteins, Apolipoprotein-ciii and Lipoproteint A) in Familial Combined Hyperlipidaemia (0)
Vasculaire geneeskunde in beeld (2012) (0)
Chylomicron apolipoprotein B catabolism (1984) (0)
Lipopolysaccharide binds and stimulates mononuclear cells before neutralization by circulating lipoproteins can occur (1997) (0)
UvA-DARE ( Digital Academic Repository ) Familial hypercholesterolemia in childhood : diagnostics , therapeutical options and risk stratification (2009) (0)
Casus 35 – Antwoord (2012) (0)
Casus 17 – Antwoord (2012) (0)
The additive value of measuring subclinical atherosclerosis is gender specific (2012) (0)
[No reason to start treatment with statins in patients with moderate to severe heart failure]. (2008) (0)
[Value of determining serum cholesterol levels in patients with coronary heart disease]. (1997) (0)
Abstract 3195: The APOA5 Gene is Associated with Familial Combined Hyperlipidemia and Dyslipidemia (2006) (0)
Casus 19 – Antwoord (2012) (0)
Casus 36 – Antwoord (2012) (0)
Casus 11 – Antwoord (2012) (0)
Obstructive jaundice in von Recklinghausen’s disease • Histoplasma capsulatum in chronic lymphocytic leukaemia . Exposure to calcium and phosphate in kidney disease Euthyroid enlargement of the thyroid gland: what is your diagnosis? (2010) (0)
Fatty Acid Composition and Vitamin E Content of Experimental Diets Component Study Diet Oleic Linoleic Oleic (2017) (0)
Diagnosis and treatment of dyslipidemias (2008) (0)
PCV15 LOW GOAL ATTAINMENT IN COMMON DAILY PRACTICE AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE NETHERLANDS:THE REALITY-PHARMO STUDY (2003) (0)
α-Tocopherol does not suppress elevated plasma levels of soluble intercellular adhesion molecule-1 and igG autoantibodies against oxidized LDL in male smokers (2000) (0)
Familial Apolipoprotein CII Deficiency: An Analysis of the Gene Defect in a Dutch Family (1986) (0)
Original article Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study (2009) (0)
Tu-P9:345 Determinants of an increased intima media thickness in patients with familial combined hyperlipidemia (FCH) (2006) (0)
[Cholesterol reducing food certainly is useful]. (1997) (0)
Management of serum lipid levels into the next millennium: new targets for treatment. (1999) (0)
Casus 13 – Antwoord (2012) (0)
The relevance of apolipoprotein B and small dense LDL as diagnostic criteria for familial combined hyperlipidemia (2001) (0)
PNMDEMACKER, RWB SCHADE, A F H STALENHOEF, P M J STUYT, Avan'tLAAR (2016) (0)
Response to Howard and Howard (1998) (0)
W01.88 Reduction of plasma oxidized LDL concentration but not change of LDL oxidation level following treatment of familial hypercholesterolemia patients with statins (2004) (0)
Peripheral vascular disease in the LDL-Apheresis Atherosclerosis Regression Study (LAARS) (1995) (0)
Casus 33 – Antwoord (2012) (0)
62. Cytokine production by mononuclear cells of patients with familial hypercholesterolemia (1997) (0)
The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemiasâƒž (2006) (0)
W14.396 The effects of paraoxonase on cholesterol lowering by simvastatin and atorvastatin (2004) (0)
Effect of low-density-lipoprotein apheresis on coronary anatomy and regional myocardial blood flow (1996) (0)
Book Review Drug Treatment of Hyperlipidemia Edited by Basil M. Rifkind. 270 pp., illustrated. New York, Marcel Dekker, 1991. $79.95. ISBN 0–8247–8512–6 . (1992) (0)
Casus 18 – Antwoord (2012) (0)
The influence of mutations in apolipoprotein c3, lipoprotein lipase and hepatic lipase on the expression of type iii hyperlipoproteinemia (2000) (0)
Effect of drug treatment in patients with familial combined hyperlipidaemia (1997) (0)
Rosuvastatin has greater beneficial effects than atorvastatin on LDL‐C, HDL‐C and apolipoproteins A‐I and B in subjects with the metabolic syndrome (2005) (0)
Casus 5 – Antwoord (2012) (0)
Casus 2 – Antwoord (2012) (0)
Macrophage heterogeneity in human carotid artery atherosclerotic plaques: identification of novel markers for M1 and M2 that are independent of the activation status (2016) (0)
Human hypo- and hyperresponders to dietary cholesterol differ in the responsiveness of their low density lipoprotein production. (1986) (0)
Casus 3 – Antwoord (2012) (0)
W17-P-019 Variation of non-invasive measurements of atherosclerosis in healthy volunteers during daytime (2005) (0)
Impact of Interleukin-18 and Obesity on Subclinical Atherosclerosis in the General Population (2010) (0)
Metabolism of apolipoproteins B-48 lipoproteins in normal and lipoprot (2016) (0)
Casus 16 – Antwoord (2012) (0)
Casus 15 – Antwoord (2012) (0)
Red wine consumption does not affect the oxidation of low-density lipoproteins in humans. (1995) (0)
Metabolic studies in various forms of hypertriglyceridemia in man (1982) (0)
[Number of coronary bypass operations in The Netherlands and other western countries]. (1989) (0)
Casus 21 – Antwoord (2012) (0)
LDL oxidation and coronary atherosclerosis. (1992) (0)
W08-O-002 Decreased adiponectin levels in patients with familial combined hyperlipidemia (2005) (0)
Improving regional myocardial perfusion with low-density lipoprotein apheresis (1997) (0)
1. Increased diffusion of chylomicron lipids to apo B-100 containing triglyceride-rich lipoproteins as a major cause for accumulation of ß-VLDL in familial dysbetalipoproteinemia (1997) (0)
Aggressive lipid lowering treatment in coronary atherosclerosis. (1997) (0)
WAIST CIRCUMFERENCE IS A BETTER PREDICTOR OF SUBCLINICAL ATHEROSCLEROSIS THAN ADIPONECTIN LEVEL (2009) (0)
Phospholipids Present in Oxidized Low-Density Lipoprotein C-Reactive Protein and Annexin A5 Bind to Distinct Sites of Negatively Charged (2017) (0)
Carotid and femoral intima media thickness and plaques in patients with familial hypercholesterolemia (2000) (0)
Casus 34 – Antwoord (2012) (0)
Casus 22 – Antwoord (2012) (0)
Casus 8 – Antwoord (2012) (0)
Abstract: P731 DIFFERENTIAL ACCUMULATION OF OXIDIZED LDL IN M1 AND M2 MACROPHAGES (2009) (0)
W04.150 Leptin levels in subjects with familial combined hyperlipidemia (2004) (0)
Cholesterol to protein ratio of very low density lipoproteins determines the low density lipoprotein subfraction profile in familial combined hyperlipidemia (1995) (0)
PO3-81 PARABOLIC RELATION BETWEEN PLASMA TRIGLYCERIDES AND LDL-CHOLESTEROL IN FAMILIAL COMBINED HYPERLIPIDEMIA: THE MULTIPLE-TYPE HYPERLIPIDEMIA EXPLAINED? (2007) (0)
ENDOTHELIAL DYSFUNCTION AS MEASURED BY FLOW MEDIATED DILATION (FMD) IN CARDIOVASCULAR RISK ASSESSMENT IN A LOW RISK POPULATION (2008) (0)
Oxidized low-density lipoprotein is not equal to oxidative stress. (2008) (0)
[Xanthelasma palpebrarum]. (1996) (0)
Casus 9 – Antwoord (2012) (0)
Casus 40 – Antwoord (2012) (0)
Casus 38 – Antwoord (2012) (0)
LDL-apheresis as treatment of severe familial hypercholesterolemia (2009) (0)
Daily consumption of non-esterified phytosterols from tall oil (Phytrol™) in a chocolate matrix significantly lowers LDL cholesterol in moderately hypercholesterolemic individuals (2000) (0)
W09.263 Reminant-like lipoprotein cholesterol levels are associated with an increased risk of cardiovascular disease in familial combined hyperlipidemia (2004) (0)
PO23-738 EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ON LOW-DENSITY AND HIGH DENSITY LIPOPROTEIN PARTICLE CONCENTRATIONS IN PATIENTS WITH METABOLIC SYNDROME (2007) (0)
[Diagnosis of 5 patients with possible primary hemochromatosis]. (2003) (0)
Erratum to Letter to the Editor: “Anti-TNF therapy and plasma HDL cholesterol concentration” [Atherosclerosis 182 (2005) 375] (2006) (0)
Determinants for Iron Overload-Related Disease in Siblings of Probands with Clinically Detected HFE Hereditary Hemochromatosis (2008) (0)
Casus 25 – Antwoord (2012) (0)
Casus 1 – Antwoord (2012) (0)
Abstracts of papers (2005) (0)
Abstracts of papers (1966) (0)
Novel approaches in the treatment of dyslipidemias (2013) (0)
5-Year Follow-Up Study Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a (2017) (0)
Abstract: 577 COLESEVELAM ADDED TO STABLE COMBINATION OF STATIN AND EZETIMIBE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA; THE TRIPLE TRIAL (2009) (0)
Casus 20 – Antwoord (2012) (0)
We-W30:6 The APOAV gene is associated with familial combined hyperlipidemia and dyslipidemia (2006) (0)
Casus 28 – Antwoord (2012) (0)
Casus 29 – Antwoord (2012) (0)
2.W15.5 Familial combined hyperlipidemia (FCH): Causes and consequences (1997) (0)
PO10-274 RATIO OF PLASMA OXIDIZED LOW-DENSITY LIPOPROTEIN AND ANNEXIN A5 POSITIVELY RELATES TO SEVERITY OF CARDIOVASCULAR DISEASE (2007) (0)
Abstract 2223: Carotid Intima Media Thickness Progression is Modest in Statin-Treated Familial Hypercholesterolemia Patients - Results from a Patient Level Meta-Analysis of 1257 Patients (2008) (0)
Endothelial dysfunction as measured by flow mediated dilatation (FMD) in cardiovascular risk assessment (2007) (0)
LDL CHOLESTEROL AND TROGLITAZONE THERAPY. AUTHORS' REPLY (1998) (0)
Absence of glomerulosclerosis in Watanabe heritable hyperlipidemic rabbits. (1993) (0)
Casus 26 – Antwoord (2012) (0)
Casus 4 – Antwoord (2012) (0)
Effect of treatment with gemfibrozil or simvastatin of patients with familial combined hyperlipidemia (FCHL) on LDL subfraction profile and LDL oxidizability (1994) (0)
Casus 6 – Antwoord (2012) (0)
Effect of lipid lowering therapy on myocardial perfusion; results from REGRESS and LAARS (1998) (0)
The Netherlands Journal of Medicine: seven years editorial office in Nijmegen, entering a new era. (2008) (0)
Effects of Partial Ileal Bypass Surgery on Low-Density Lipoprotein Metabolism in Watanabe Heritable Hyperlipidemic Rabbits (1987) (0)
67 Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking (1997) (0)
[Cardiovascular prevention in the over-80 age group is beneficial]. (2008) (0)
Casus 32 – Antwoord (2012) (0)
P364 OXIDIZED LDL EXPOSURE DECREASES KR ÜPPEL-LIKE FACTOR 2 EXPRESSION AND INCREASES PRO-INFLAMMATORY CAPACITY OF M2 MACROPHAGES (2010) (0)
Casus 12 – Antwoord (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Anton F. H. Stalenhoef?

Anton F. H. Stalenhoef is affiliated with the following schools: